Clinical Phase 2Neuroprotection & LongevityNot a peptide — synthetic research compound

J-147

Synthetic small molecule (curcumin derivative, hydrazone structure) · J147 · CAS no. 1146963-51-0

J-147 is an experimental, small-molecule drug candidate (not a peptide) originally developed against Alzheimer's disease and general brain aging. Its approach differs fundamentally from the classic amyloid strategies: instead of breaking down plaques, J-147 stabilizes the mitochondrial energy metabolism of the nerve cell. The preclinical evidence (cell/animal) is broad and mechanistically well founded; in humans the substance has so far only been tested in one completed, unpublished Phase 1 trial and is not approved for any use. This profile puts the current state into context – without any dosing or usage instructions.

Machine-assisted translation. The German original is the authoritative version.

At a glance

Substance class: Synthetic small molecule (curcumin derivative) – not a peptide
CAS number: 1146963-51-0
Origin: Salk Institute, David Schubert laboratory (from 2011)
Clinical developer: Abrexa Pharmaceuticals, Inc.
Primary molecular target: α-F1 subunit of mitochondrial ATP synthase (ATP5A)
CNS penetration: Crosses the blood-brain barrier
Development status: Phase 1 completed (2020); Phase 2 in preparation
Approval: None – purely experimental

Origin & development

J-147 was developed from 2011 onward at the Salk Institute for Biological Studies in the laboratory of David Schubert. Unlike most Alzheimer's drugs, which specifically target the amyloid-beta protein, J-147 emerged from a phenotypic screening: synthetic molecules derived from natural compounds were tested directly on living nerve cells to see whether they could block or reverse cellular aging processes.

The starting point was the plant polyphenol curcumin, which has interesting properties but poor bioavailability and barely any neurotrophic activity. The researchers combined structural elements of curcumin with a more nerve-active compound; through further chemical optimization, the intermediate CNB-001 ultimately gave rise to J-147 – more stable, more potent, and able to efficiently cross the blood-brain barrier.

Mechanism of action: energy metabolism instead of amyloid

The primary molecular target of J-147 was identified in 2018 (Goldberg et al., Aging Cell): the substance binds to the α-F1 subunit of mitochondrial ATP synthase (ATP5A) – the enzyme that produces the energy currency ATP. However, J-147 inhibits this enzyme only partially and in a saturated manner, not completely. This subtle brake distinguishes it from toxic full blockers and acts as a targeted stress stimulus that triggers a protective adaptive response in the cell.

The slight throttling leads to a brief rise in calcium within the cell, which activates the central energy switch AMPK via the kinase CaMKK2. Because this pathway runs through calcium, the cell can ramp up its energy production without ATP levels themselves dropping. The result is increased mitochondrial respiratory capacity, preservation of the mitochondrial membrane potential, and stimulated formation of new mitochondria – precisely those processes that decline with aging and neurodegeneration.

Primary target (identified in 2018): α-F1 subunit of ATP synthase (ATP5A).
Only partial, saturated inhibition – a stimulus, not a poison (unlike full blockers).
Trigger cascade: calcium → CaMKK2 → AMPK; energy production rises without ATP falling.
Targets the energy metabolism – not primarily amyloid like classic Alzheimer's drugs.

Anti-inflammatory action: repolarizing the microglia

More recent preclinical data (2025) show that J-147 also influences the brain's immune cells – the microglia – via the same CaMKK2/AMPK signaling pathway. In cell and animal models of induced brain inflammation, J-147 shifts the microglia from a pro-inflammatory ("M1") toward an anti-inflammatory, protective state ("M2").

The consequence is a reduced release of inflammatory messengers (such as TNF-α and interleukin-6) alongside increased production of the protective interleukin-10. If the CaMKK2/AMPK pathway is specifically blocked, these effects disappear – an indication that the anti-inflammatory action genuinely depends on this cascade.

J-147 shifts microglia from the inflammatory (M1) to the protective (M2) state.
Fewer inflammatory messengers (TNF-α, IL-6), more protective IL-10.
The effect disappears when the CaMKK2/AMPK pathway is blocked (mechanism confirmed).
Evidence level: preclinical (cell/animal), 2025 – not demonstrated in humans.

Preclinical spectrum of activity

The strength of J-147 in research is its breadth: because it targets a central metabolic interface, it shows effects across very different disease models. Important for context: all of this comes from cell cultures and animal models, not from humans.

In Alzheimer's mouse models, long-term administration of J-147 reduced amyloid deposits and reversed memory deficits. In accelerated aging models it stabilized mitochondrial and epigenetic markers; in the fruit fly it extended lifespan by around 13%. In stroke models, J-147 reduced the volume of damage and – in combination with the clot-dissolving agent t-PA – the feared brain hemorrhages as well as mortality. Further models cover traumatic brain injury, diabetic nerve damage, and postoperative cognitive impairment. For the hereditary nerve disorder Charcot-Marie-Tooth type 1A, J-147 (or the related molecule CMS121) has so far merely been proposed as a possible approach – proof of efficacy in corresponding models is still pending.

Alzheimer's mouse models: less amyloid, reversal of memory deficits.
Aging: stabilized mitochondrial/epigenetic markers; ~13% longer lifespan in the fruit fly.
Stroke: smaller damage volume; with t-PA, fewer brain hemorrhages and lower mortality.
Further models: brain trauma, diabetic neuropathy, postoperative cognitive impairment; CMT1A so far only proposed as a hypothesis (CMS121).
All findings are preclinical – their transferability to humans remains open.

Safety profile and possible interactions

In preclinical testing, J-147 is considered well tolerated: it was unremarkable in the Ames test (genotoxicity) and the hERG test (cardiac rhythm) and showed a wide margin between effective and harmful concentrations in toxicological studies. This is not, however, proof of safety in humans – robust human data on long-term safety are lacking.

From the mechanism of action arise theoretical interaction risks that are discussed in research: because J-147 stimulates the AMPK/mTOR metabolic pathway, its effects could overlap with substances such as metformin or rapamycin. In addition, J-147 inhibits the dopamine transporter, which is why, from a research perspective, combining it with dopaminergic agents would require particular caution. These points are reasons why such substances belong in medical hands – and not an indication of any use outside of clinical trials.

Preclinically unremarkable in the Ames test (genotoxicity) and hERG test (heart); wide therapeutic margin.
No robust human data on long-term safety.
Theoretical interactions: AMPK/mTOR modulators (e.g. metformin, rapamycin).
Inhibits the dopamine transporter → discussed caution with dopaminergic agents.

Clinical trials

Phase 1NCT03838185 ↗

Safety, tolerability & pharmacokinetics in healthy subjects

Completed (2020) – results unpublished

Randomized, double-blind, placebo-controlled; single ascending oral doses (SAD) in 64 healthy younger and older subjects. Tolerability was sufficient to justify the transition into Phase 2; however, detailed results have not been published to date, so an independent assessment is not possible.

Phase 2NCT07430917 ↗

Acute ischemic stroke (JUMPSTART)

Not yet recruiting (planned start 2026)

Planned adaptive Phase 2 trial on adjunctive neuroprotection after mechanical thrombectomy. Led among others by Steven J. Warach (UT Austin). A definitive assessment of the clinical benefit is only possible after completion.

Regulatory status

General

Experimental – not approved anywhere

J-147 is a pure investigational/research compound without any pharmaceutical approval for use in humans.

Germany (AMG)

Import/use of unapproved medicinal products is a criminal offense

The German Medicines Act (AMG) criminalizes the import and use of unapproved agents – declaring it a "dietary supplement" abroad does not change this.

Sport (WADA)

Non-approved substance

Unapproved investigational substances fall under the general prohibition of non-approved substances (category S0).

Safety & context

J-147 is exclusively a research compound – there is no approved use and no established human evidence of benefit or long-term safety.
All efficacy evidence comes from cell and animal models; neuroprotective substances have historically failed very frequently in the leap from animal to human.
The results of the Phase 1 trial already completed in 2020 were never published in detail – an independent assessment of human safety is therefore not possible.
Material traded freely on the internet as a "research chemical" is subject to no quality control (purity, impurities unclear) and is legally precarious.
This profile deliberately states no dosages, reconstitution, or usage protocols.

Related peptide profiles

Epitalon (Epithalon)

Synthetic tetrapeptide — research substance for aging, not approved.

Humanin

Mitochondria-derived 24-amino-acid peptide from neuro- and longevity research — experimental, not approved.

MOTS-c

A mitochondrially encoded peptide — an "exercise mimetic" of research, not approved.

SS-31 (Elamipretid)

A cardiolipin-stabilizing mitochondrial peptide — approved in the USA for Barth syndrome in 2025.

Frequently asked questions

Is J-147 a peptide?: No. J-147 is a synthetic, small-molecule compound (an optimized curcumin derivative). It is listed here under "Research Compounds" because it is not a peptide and therefore does not belong in the peptide catalog – though the research questions (neuroprotection, brain aging) do overlap.
Can you take J-147 against Alzheimer's or for "brain rejuvenation"?: No. J-147 is not approved for any use. The promising data come from cell and animal experiments; in humans, only safety has so far been studied in a small, unpublished Phase 1 trial. A benefit in humans is not established.
What is special about the mechanism of action?: J-147 does not target amyloid but the energy metabolism of the nerve cell: it slightly slows mitochondrial ATP synthase and thereby triggers a protective adaptation (CaMKK2/AMPK). This metabolic approach explains why it works across very different disease models – but so far it is only demonstrated preclinically.

Sources

This profile is for information and education only. It does not replace medical advice and deliberately contains no dosing, reconstitution, usage or sourcing information.

← All research compounds